

Lene Jensen
CEO
Rare Disease Denmark
Blekinge Boulevard 2
22630 Taastrup
Denmark

14 February 2020

Dear Lene,

Confirmation of Charitable Contribution

Ref: 2019-0063 Rare Diseases Denmark

Thank you for your application for funding for Rare Disease Denmark. Amicus Therapeutics UK Limited ("Amicus") is pleased to confirm funding of 25,000Kr to support activities planned for Rare Disease Day 29th February 2020 that include exhibitions titled 'Empowerment through Bella Speranza' and 'Me and my rare diagnosis' as well as a social media campaign during the month of February 2020. These are all aimed to raise awareness and share experiences of living with rare diseases.

For clarity, Rare Disease Denmark will be solely responsible for organising and implementing the activities outlined in the request letter and Amicus will have no influence or control over how the funds are spent, beyond agreeing to the funding.

Amicus will have no influence over the content and will have no commercial interest or gain from any activities or materials generated as a result of this charitable contribution. Final editorial control and responsibility for the content of the materials always strictly remains with Rare Diseases Denmark.

Rare Disease Denmark agrees that all activities conducted by the organisation that are funded by Amicus will be conducted in line with applicable country industry codes and regulations.

As required by the Association of the British Pharmaceutical Industry (ABPI) Code of Practice, Amicus will ensure any funding provided is acknowledged and publicly declared, along with the nature of the company's involvement. We request all patient organisations we work with report their funding sources as required and include funding received from Amicus.

To avoid any potential conflicts of interest, please can Rare Disease Denmark let Amicus know if any Officer or Beneficiaries of the organisation are a Government Official, or affiliated with a government agency. This includes any role making decisions on advising government of the regulation of medicines or prescribing policy or funding /provision of healthcare at a national or international level.

Amicus will not make use of Rare Disease Denmark logo or equivalent without your prior agreement. Any use of the Amicus logo must be agreed beforehand and be in line with Amicus policies and branding guidelines.

At the event, Amicus's support must be clearly disclosed as having provided an unrestricted charitable contribution. In addition, any materials generated as a result of this funding must include the following statement of acknowledgement – 'These materials have been supported by an unrestricted charitable contribution from Amicus Therapeutics UK Limited'.

Please sign and return a copy of this letter and send an invoice addressed to: Amicus Therapeutics UK, One Globeside, Fieldhouse Lane, Marlow, Buckinghamshire, SL7 1HZ, UK. Please ensure the invoice includes: the bank account information such as SWIFT code, account number, transit number and the following purchase order number INTL001389 specific to your application. If you have any question relating to this please contact patientadvocacyintl@amicusrx.com.

Finally, when working with patient organisations, as our International headquarters are based in the UK, all our charitable contributions have to adhere to the standards laid out by the ABPI Code of Practice.

With kind regards,



Simon Jordan
Senior Vice President, International

By signing below, Rare Disease Denmark acknowledges receipt of this letter and accepts the terms of the financial contribution described above.

For and on behalf of
Rare Disease Denmark
Duly Authorised

SJÆLDNE DIAGNOSER
Blekinge Boulevard 2
DK-2630 Taastrup
Denmark
CVR-nr.: 20 51 48 92

Date:

17/2-20 